10-Q: Leap Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Leap Therapeutics reported its second quarter 2024 financial results, highlighting progress in clinical trials and a recent $40 million private placement.

Summary

• Leap Therapeutics reported a net loss of $20.4 million for the three months ended June 30, 2024, and a net loss of $34.2 million for the six months ended June 30, 2024.
• Research and development expenses were $17.9 million for the three months ended June 30, 2024, and $29.2 million for the six months ended June 30, 2024.
• The company completed a $40 million private placement in April 2024, resulting in net proceeds of $37.1 million.
• As of June 30, 2024, Leap Therapeutics had cash and cash equivalents of $78.5 million.
• The company expects its current cash reserves to fund operations into the second quarter of 2026.
• The DeFianCe study, evaluating DKN-01 in colorectal cancer, showed a 33% overall response rate in response-evaluable patients.
• Enrollment in Part B of the DeFianCe study is ongoing and expected to be completed by the end of September 2024.
• The DisTinGuish study, evaluating DKN-01 in gastric cancer, is ongoing with initial data expected in Q4 2024 or early 2025.

Sentiment

Score: 7

Explanation: The document presents a mix of positive and negative aspects. The successful private placement and promising clinical trial results are positive, but the ongoing losses and dependence on future funding are concerning. The overall sentiment is cautiously optimistic.

Positives

• The $40 million private placement provides substantial funding to support operations into the second quarter of 2026.
• The DeFianCe study shows promising clinical activity of DKN-01 in colorectal cancer, particularly in patients with left-sided tumors.
• The company has a strong cash position of $78.5 million, providing financial stability.
• The expansion of the DeFianCe study and the ongoing DisTinGuish study indicate continued progress in clinical development.
• The company is actively managing its research and development programs and is making progress in its clinical trials.

Negatives

• The company continues to incur significant net losses, with a $20.4 million loss for the quarter and a $34.2 million loss for the six-month period.
• Research and development expenses remain high, reflecting the costs of ongoing clinical trials.
• The company has not yet generated any revenue from product sales.
• The company is dependent on raising additional capital to fund its operations.

Risks

• The company's future operations are dependent on the success of its efforts to raise additional capital.
• The company's product candidates are still in clinical development and may not receive regulatory approval.
• The company may experience delays in clinical trials or other research and development programs.
• The company's product candidates may not achieve market acceptance.
• The company faces competition from other therapies that may become available.

Future Outlook

The company expects its current cash reserves to fund operations into the second quarter of 2026. Initial data from Part C of the DisTinGuish study is expected in Q4 2024 or early 2025. Enrollment in Part B of the DeFianCe study is expected to be completed by the end of September 2024, with data expected mid-2025.

Management Comments

• The net proceeds from this financing, combined with existing cash, cash equivalents and marketable securities, are expected to fund our operating and capital expenditures into the second quarter of 2026 and enable expansion of the DKN-01 DeFianCe clinical trial and development program.

Industry Context

Leap Therapeutics is operating in the competitive biopharmaceutical industry, focusing on developing novel antibody therapies for cancer. The company's focus on biomarker-targeted therapies aligns with current trends in oncology drug development. The company's collaboration with Adimab and NovaRock is consistent with industry practices of partnering to leverage expertise and resources.

Comparison to Industry Standards

• The reported ORR of 33% in the DeFianCe study is within the range of other second-line colorectal cancer treatments, but the enhanced activity in left-sided tumors is a notable positive.
• The company's cash runway into the second quarter of 2026 is relatively strong compared to other clinical-stage biotechs, providing financial stability for ongoing development.
• The company's R&D spending is typical for a company in its stage of development, with a focus on clinical trials and manufacturing.
• The company's reliance on private placements for funding is common in the biotech industry, but also highlights the need for future capital raises.

Stakeholder Impact

• Shareholders benefit from the company's progress in clinical trials and the secured funding.
• Employees are supported by the company's financial stability and ongoing research activities.
• Patients may benefit from the development of new cancer therapies.
• Creditors are supported by the company's cash position and ability to meet its obligations.

Next Steps

• Complete enrollment in Part B of the DeFianCe study by the end of September 2024.
• Report initial data from Part C of the DisTinGuish study in Q4 2024 or early 2025.
• Continue clinical development of DKN-01 and other product candidates.
• Seek additional funding through public or private equity financings or government programs.

Key Dates

Keywords

DKN-01, FL-301, colorectal cancer, gastric cancer, clinical trials, biopharmaceutical, antibody therapy, private placement, research and development, oncology